Patents Examined by Maria G Leavitt
  • Patent number: 11977073
    Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: May 7, 2024
    Assignee: AgeX Therapeutics, Inc.
    Inventor: Basil M. Hantash
  • Patent number: 11976117
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: May 7, 2024
    Assignee: McMaster University
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • Patent number: 11970718
    Abstract: An extracellular vesicle loaded with a nucleic acid cargo and method for preparing the loaded vesicle is disclosed.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: April 30, 2024
    Assignee: Carmine Therapeutics Pte. Ltd.
    Inventors: Harvey Lodish, Ronne Yeo, Waqas Muhammad Usman, Tenzin Gocha
  • Patent number: 11957115
    Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods ace provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: April 16, 2024
    Assignees: The Jackson Laboratory, Indiana University Research and Technology Corporation
    Inventors: Gareth Howell, Michael Sasner, Gregory Carter, Bruce Lamb
  • Patent number: 11945865
    Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: April 2, 2024
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Yi Tian Png, Natasha Vinanica, Takahiro Kamiya, Dario Campana
  • Patent number: 11931408
    Abstract: Embodiments of the disclosure concern methods of identifying whether or not antigens from a particular pathogen are immunogenic, including the order of their immunogenicity. Other embodiments concern correlations between attributes of T cells and their clinical efficacy, such as mathematical representations thereof.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: March 19, 2024
    Assignee: Baylor College of Medicine
    Inventors: Ann Marie Leen, Pailbel Aguayo-Hiraldo, Ifigeneia Tzannou, Juan F. Vera Valdes
  • Patent number: 11903972
    Abstract: Disclosed herein are cell preparations useful for modulating various peripheral immune functions, methods for making said cell preparations, and methods for their use.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: February 20, 2024
    Assignee: SanBio, Inc.
    Inventors: Mo Dao, Casey C Case
  • Patent number: 11896615
    Abstract: Provided are methods of treatment involving immunotherapy, such as T cell therapy, and administration of a tryptophan metabolism and/or kynurenine pathway modulator. In some embodiments, the method includes a combination therapy that involves administration of engineered T cells, such as chimeric antigen receptor (CAR)-expressing cells, and a tryptophan metabolism and/or kynurenine pathway modulator, such as an inhibitor of an enzyme. Also provided are engineered cells in which the expression of a molecule involved in the kynurenine pathway is modified. Also provided are methods of manufacturing engineered cells, cells, compositions, methods of administration to subjects, nucleic acids and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, activity, outcome, function, response, persistence, expansion and/or proliferation of cells for adoptive cell therapy.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: February 13, 2024
    Assignee: Juno Therapeutics, Inc.
    Inventors: Michael Ports, Evan Paul Thomas, Hyam I. Levitsky
  • Patent number: 11883432
    Abstract: The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have adaptable receptor specificity (arCARs). Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: January 30, 2024
    Assignee: CENTURY THERAPEUTICS, INC.
    Inventors: Jill Marinari Carton, Michael Francis Naso, Luis Ghira Borges, John Wheeler, Andrew Devaney
  • Patent number: 11884716
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: January 30, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Saar Gill, Jonathan Hogan, Aimee S. Payne, Baomei Wang
  • Patent number: 11878035
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: January 23, 2024
    Assignees: Triumvira Immunologics USA, Inc., McMaster University
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • Patent number: 11851649
    Abstract: Aspects of the invention described herein relate to methods of making and using inducible promoters for transgene expression. The inducible promoters are derived from the NFAT-RE inducible system and are used to improve or enhance T cell survival and proliferation.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: December 26, 2023
    Assignee: Seattle Children's Hospital
    Inventors: Jia Wei, Michael C. Jensen
  • Patent number: 11849709
    Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: December 26, 2023
    Assignee: Hera Testing Laboratories, Inc.
    Inventors: Eric M. Ostertag, John Stuart Crawford, Joseph Ruiz
  • Patent number: 11851491
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 26, 2023
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Robert Hofmeister
  • Patent number: 11845956
    Abstract: Certain populations of small cells present in adult human tissue can undergo activation/development to form human pluripotent stem cell populations. These small cells are generally less than six micrometers in diameter and are CD49f-positive, and are referred to herein as human early stage precursors or CD49f+ cells. Accordingly, provided are cell populations and compositions with enriched CD49f+ cells from adult human tissue samples and methods and compositions for promoting activation/development of these CD49f+ cells. Upon differentiation, the activated stem cells can be used for various therapeutic purposes.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 19, 2023
    Assignee: APstem Therapeutics, Inc.
    Inventors: Shaowei Li, Min Hu, Bowen Liu
  • Patent number: 11827904
    Abstract: Stem cells are modified to express an extracellular component including a tag cassette. The tag cassette can be used to detect, enrich, isolate, activate, track, deplete, or eliminate modified cells. The cells can be administered before or following differentiation into a more committed cell type.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: November 28, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Colleen Delaney, Stanley R. Riddell
  • Patent number: 11820819
    Abstract: The present disclosure provides chimeric antigen receptors, compostions, and methods thereof. In one embodiment the present disclosure provides a method of treating autoimmune diseases, asthma, and preventing or mediating organ rejection in a subject.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: November 21, 2023
    Assignee: iCell Gene Therapeutics Inc.
    Inventors: Yupo Ma, Kevin Pinz, Xun Jiang, Masayuki Wada, Kevin Chen
  • Patent number: 11771763
    Abstract: The present invention provides compositions and methods for the selective silencing of neurons in pain pathway by using a combination of inhibitory light-sensitive protein gene transfer and wavelength specific illumination.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: October 3, 2023
    Assignees: EOS NEUROSCIENCE, INC., WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Alan Horsager, Kenneth Greenberg, Benjamin C. Matteo, Edward S. Boyden, Douglas G. Ririe, James C. Eisenach, Christian Wentz
  • Patent number: 11753626
    Abstract: Provided are suspension-based cell culture systems and media for the timely and efficient proliferation of human tumor cell clusters from a patient, and related methods of evaluating the potential responsiveness of the tumor cells and the patient to one or more therapeutic agents.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: September 12, 2023
    Inventors: Yiyou Chen, Zhen Yang, Yihong Zhang
  • Patent number: 11739129
    Abstract: The present disclosure provides a mutated form of AP4 that is more resistant to degradation relative to wild-type AP4. The disclosure also provides T cells expressing the mutated form of AP4 and methods of using the T cells in adoptive cellular immunotherapy.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: August 29, 2023
    Assignee: Washington University
    Inventors: Takeshi Egawa, Chun Chou